An interventional study of Noninvasive spinal stimulation with gait training and Conventional gait training in Stroke, sponsored by Shirley Ryan AbilityLab. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Shirley Ryan AbilityLab · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Stroke by Shirley Ryan AbilityLab — 12 open to participants now, 20 under way, none of them phase 3. Stroke · Shirley Ryan AbilityLab.
Among the 64 studies in Stroke by Shirley Ryan AbilityLab, this one is the 3rd largest by planned enrollment of the 55 interventional ones that give a count, is one of 8 that started in 2022, is one of 49 with no phase, reaches primary completion later than 14 of the 19 other live ones, and was the 46th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →12 of the 64 studies in Stroke by Shirley Ryan AbilityLab are open now, in 1 country. Recruiting first, the newest first:
Shirley Ryan AbilityLab · Sites in United States
Ages 18+
Shirley Ryan AbilityLab · Sites in United States
Ages 40–70 · Healthy volunteers
Shirley Ryan AbilityLab · Sites in United States
Ages 18+ · Healthy volunteers
Shirley Ryan AbilityLab · Sites in United States
Ages 18+
Shirley Ryan AbilityLab · Sites in United States
Ages 18–89
By country, each count listing its studies:
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 2
First in 2003; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 115 is above the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 30 across the 55 interventional studies, 40 across the 9 observational. Of the 32 that completed or were terminated, 12 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Shirley Ryan AbilityLab is the lead sponsor of 181 studies on the registry; 44 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 4 (40%) have results posted.
7 of the studies in Stroke by Shirley Ryan AbilityLab that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03300141Shirley Ryan AbilityLabLooking Glass: Bimanual Balanced Reaching With Visual Biofeedback | 2026-12 |
| NCT05076565Shirley Ryan AbilityLabWearable Airbag Technology to Mitigate Falls in Individuals With High Fall Risk | 2026-12-14 |
| NCT05471375Shirley Ryan AbilityLabC-STAR Movement Database | 2026-12-31 |
| NCT06234124Shirley Ryan AbilityLabCharacterization and Clinical Trial of a Variable Friction Shoe | 2027-01 |
| NCT06663501Shirley Ryan AbilityLabEffects of Vibration on Motor Function of Survivors of Chronic Stroke | 2027-03-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 64 studies in Stroke by Shirley Ryan AbilityLab, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study has two interventional components, the first is a cross-over design and the second is a randomized control trial. Both will evaluate the effectiveness of transcutaneous (non-invasive) spinal cord stimulation on gait and balance function for individuals with hemiplegia due to stroke.
OBJECTIVES:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
TMS-Specific Exclusion Criteria: TMS will be utilized for both Aims. The sub-set of participants who meet these criteria will participate in this component of the studies.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Up to 60 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
Device: Noninvasive spinal stimulation with gait training · Other: Exploratory Phase - Optimization of Gait Training and Spinal Stimulation
Up to 30 seconds of transcutaneous spinal cord stimulation in order to blind them to the intervention while performing locomotion training. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
Device: Conventional gait training
Up to 60 min of locomotion training with transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
Device: Noninvasive spinal stimulation with gait training · Other: Exploratory Phase - Optimization of Gait Training and Spinal Stimulation
Up to 30 seconds of transcutaneous spinal cord stimulation in order to blind them to the intervention while performing locomotion training. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
Device: Conventional gait training
Transcutaneous Spinal Cord Neurostimulator will deliver transcutaneous electrical spinal cord stimulation while subjects perform lower limb locomotor activities.
Subjects will receive lower limb locomotion training without transcutaneous spinal cord stimulation. However, the amount of time spent in side-lying locomotion training, treadmill training and over ground training will depend on individual tolerance and progression.
Subjects may receive various lower limb locomotion training with or without transcutaneous spinal cord stimulation. Training approaches may include but are not limited to single or split belt treadmill and over ground walking. Transcutaneous Spinal Cord Neurostimulator may deliver a variety of transcutaneous electrical spinal cord stimulation to subjects.
Change in Gait Symmetry
Participants will ambulate along Gait Rite electronic walkway 3 times per gait speed to evaluate gait pattern at both their self-selected and safe fast gait speed. The GAITRite electronic walkway contains sensor pads encapsulated in a carpet and connected to a computer. The system can be laid over any flat surface and automates measuring temporal and spatial gait parameters. The GAITRite electronic walkway for the study shall be a minimum of 14 feet long. The GAITRite data capture was chosen as measurement of the patient's overall gait quality.
Time frame: Aim 1: Baseline pre-intervention immediately post intervention for interventions 1, 2, 3 and 4. Aim 2: Baseline pre-intervention, 4 weeks into the intervention, immediately post intervention and 3 months post intervention for intervention 1 and 2.
Change in 6 Minute Walk Test
The 6 Minute Walk Test (6MWT) measures the distance a subject can walk indoors on a flat, hard surface in a period of 6 minutes, using assistive devices, as necessary. The test is a reliable and valid evaluation of functional exercise capacity and is used as a sub-maximal test of aerobic capacity and endurance. The test will be used to determine participant's gait efficiency at baseline and at study completion. The walk test is patient self-paced and assesses the level of functional capacity. Patients are allowed to stop and rest during the test, however, the timer does not stop. If the patient is unable to complete the time, the time stopped is noted and reason for stopping prematurely is recorded. This test will be administered while wearing a portable gas analysis system called the Cosmed K4B2 to measure oxygen consumption. This system measures oxygen consumption (VO2) and Carbon-dioxide production (VCO2) in a breath by breath fashion.
Time frame: Aim 2: Baseline pre-intervention, 4 weeks into the intervention, immediately post intervention and 3 months post intervention for intervention 1 and 2.
Change in 10 Meter Walk Test
This test will examine the patient's gait speed. Patients will be directed to walk 3 times per gait speed to evaluate gait pattern at both their self-selected and safe fast gait speed. Patients will be positioned 1 meter before the start line and instructed to walk the entire distance and past the end line approximately 1 meter. The distance before and after the course are meant to minimize the effect of acceleration and deceleration. Time will be recorded using a stopwatch and recorded to the one hundredth of a second (ex: 2.15 sec).
Time frame: Aim 1: Baseline pre-intervention immediately post intervention for interventions 1, 2, 3 and 4. Aim 2: Baseline pre-intervention, 4 weeks into the intervention, immediately post intervention and 3 months post intervention for intervention 1 and 2.
Started Mar 2022 (actual). Primary completion is estimated for Jul 2027, 64 months after the start.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 64 months is above that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
Primary completion moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jul 2027, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.